Shuttle Pharmaceuticals Holdings, Inc, based in Rockville, MD, is a pioneering biopharmaceutical company focused on developing groundbreaking therapies to combat cancer and enhance the efficacy of radiation therapy. With a strong emphasis on innovation, their portfolio includes first-in-class treatments designed to sensitize cancer cells, protect normal tissues, and monitor patient responses to treatment.
Driven by a world-class team of experts, including co-founders Dr. Anatoly Dritschilo, Dr. Milton Brown, and Dr. Mira Jung, Shuttle Pharmaceuticals leverages their unparalleled scientific, clinical, and regulatory expertise to advance the discovery and development of novel small molecules. Through strategic collaborations and a platform technology, they aim to modify the effects of ionizing radiations on cancer cells and normal tissues, offering a potential game-changing approach to radiation oncology and immuno-oncology treatments.
Generated from the website